Peptide receptor radionuclide therapy
J Hofland, T Brabander, FA Verburg… - The Journal of …, 2022 - academic.oup.com
The concept of using a targeting molecule labeled with a diagnostic radionuclide for using
positron emission tomography or single photon emission computed tomography imaging …
positron emission tomography or single photon emission computed tomography imaging …
[HTML][HTML] A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
MN Becx, NS Minczeles, T Brabander, WW de Herder… - Cancers, 2022 - mdpi.com
Simple Summary Peptide receptor radionuclide therapy (PRRT) is one of the treatment
options for locally advanced or metastatic gastroenteropancreatic (GEP) neuroendocrine …
options for locally advanced or metastatic gastroenteropancreatic (GEP) neuroendocrine …
[HTML][HTML] Preclinical Evaluation of [155/161Tb]Tb-Crown-TATE—A Novel SPECT Imaging Theranostic Agent Targeting Neuroendocrine Tumours
L Wharton, SW McNeil, H Merkens, Z Yuan… - Molecules, 2023 - mdpi.com
Terbium radioisotopes (149Tb, 152Tb, 155Tb, 161Tb) offer a unique class of radionuclides
which encompass all four medicinally relevant nuclear decay modalities (α, β+, γ, β−/e−) …
which encompass all four medicinally relevant nuclear decay modalities (α, β+, γ, β−/e−) …
[HTML][HTML] Short-Interval, low-dose peptide receptor radionuclide therapy in combination with PD-1 checkpoint immunotherapy induces remission in …
A Aicher, A Sindrilaru, D Crisan, W Thaiss, J Steinacker… - Pharmaceutics, 2022 - mdpi.com
Merkel cell carcinoma (MCC) is a neuroendocrine skin cancer of the elderly, with high
metastatic potential and poor prognosis. In particular, the primary resistance to immune …
metastatic potential and poor prognosis. In particular, the primary resistance to immune …
[HTML][HTML] Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023
G di Santo, G Santo, A Sviridenko, I Virgolini - Theranostics, 2024 - ncbi.nlm.nih.gov
A growing body of literature reports on the combined use of peptide receptor radionuclide
therapy (PRRT) with other anti-tumuor therapies in order to anticipate synergistic effects with …
therapy (PRRT) with other anti-tumuor therapies in order to anticipate synergistic effects with …
[HTML][HTML] Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives
G Santo, G Di Santo, I Virgolini - Seminars in Nuclear Medicine, 2024 - Elsevier
Peptide receptor radionuclide therapy (PRRT) today is a well-established treatment strategy
for patients with neuroendocrine tumors (NET). First performed already more than 30 years …
for patients with neuroendocrine tumors (NET). First performed already more than 30 years …
Traceable calibration with 177Lu and comparison of activity meters at hospitals in Norway and Sweden
C Hindorf, L Jessen, SC Kapidzic, J Blakkisrud… - Physica Medica, 2023 - Elsevier
Introduction The activity meter is used to determine the activity of delivered
radiopharmaceuticals, administered activity to patients and reference activity when gamma …
radiopharmaceuticals, administered activity to patients and reference activity when gamma …
[PDF][PDF] Lutetium oxodotreotide for the treatment of metastatic or inoperable gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
A Dullea, M Carrigan, L O'Sullivan, KK O'Brien… - lenus.ie
Peptide receptor radionuclide therapy (PRRT) with 177Lu oxodotreotide is authorised by the
European Medicine's Agency as a treatment option for gastroenteropancreatic …
European Medicine's Agency as a treatment option for gastroenteropancreatic …